

Lindsay M Morton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2282922/publications.pdf>

Version: 2024-02-01

278
papers

14,318
citations

22153

59
h-index

23533

111
g-index

282
all docs

282
docs citations

282
times ranked

17442
citing authors

#	ARTICLE	IF	CITATIONS
1	Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. <i>Blood</i> , 2006, 107, 265-276.	1.4	1,392
2	2016 US lymphoid malignancy statistics by World Health Organization subtypes. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 443-459.	329.8	791
3	Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. <i>Blood</i> , 2012, 119, 34-43.	1.4	498
4	Reporting Participation in Epidemiologic Studies: A Survey of Practice. <i>American Journal of Epidemiology</i> , 2006, 163, 197-203.	3.4	420
5	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. <i>Nature Genetics</i> , 2020, 52, 1219-1226.	21.4	367
6	Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). <i>Blood</i> , 2007, 110, 695-708.	1.4	365
7	Hepatitis C and Non-Hodgkin Lymphoma Among 4784 Cases and 6269 Controls From the International Lymphoma Epidemiology Consortium. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 451-458.	4.4	313
8	Etiologic Heterogeneity Among Non-Hodgkin Lymphoma Subtypes: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 130-144.	2.1	265
9	Differences in incidence and trends of haematological malignancies in Japan and the United States. <i>British Journal of Haematology</i> , 2014, 164, 536-545.	2.5	250
10	Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. <i>International Journal of Cancer</i> , 2009, 125, 398-405.	5.1	221
11	Second Solid Cancers After Radiation Therapy: A Systematic Review of the Epidemiologic Studies of the Radiation Dose-Response Relationship. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 224-233.	0.8	220
12	InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. <i>Blood</i> , 2010, 116, e90-e98.	1.4	200
13	Trends in primary central nervous system lymphoma incidence and survival in the U.S.. <i>British Journal of Haematology</i> , 2016, 174, 417-424.	2.5	196
14	Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. <i>Blood</i> , 2013, 121, 2996-3004.	1.4	195
15	Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2013, 45, 868-876.	21.4	179
16	Cigarette Smoking and Risk of Non-Hodgkin Lymphoma: A Pooled Analysis from the International Lymphoma Epidemiology Consortium (InterLymph). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 925-933.	2.5	164
17	Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. <i>American Journal of Hematology</i> , 2011, 86, 206-209.	4.1	162
18	Second Malignancy Risks After Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: Differences by Lymphoma Subtype. <i>Journal of Clinical Oncology</i> , 2010, 28, 4935-4944.	1.6	161

#	ARTICLE	IF	CITATIONS
19	Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite. <i>Nature Genetics</i> , 2015, 47, 1073-1078.	21.4	157
20	Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. <i>Nature Genetics</i> , 2010, 42, 661-664.	21.4	152
21	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Follicular Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 26-40.	2.1	151
22	Proportions of Kaposi Sarcoma, Selected Non-Hodgkin Lymphomas, and Cervical Cancer in the United States Occurring in Persons With AIDS, 1980-2007. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1450.	7.4	150
23	Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era. <i>Aids</i> , 2014, 28, 2313-2318.	2.2	150
24	Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. <i>Blood</i> , 2008, 112, 5150-5160.	1.4	148
25	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. <i>Nature Genetics</i> , 2014, 46, 1233-1238.	21.4	147
26	Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-2012. <i>British Journal of Haematology</i> , 2016, 174, 382-396.	2.5	142
27	Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma. <i>JAMA Oncology</i> , 2020, 6, 724.	7.1	139
28	Alcohol consumption and risk of non-Hodgkin lymphoma: a pooled analysis. <i>Lancet Oncology</i> , The, 2005, 6, 469-476.	10.7	137
29	The Rising Incidence of Second Cancers: Patterns of Occurrence and Identification of Risk Factors for Children and Adults. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e57-e67.	3.8	129
30	Incidence of marginal zone lymphoma in the United States, 2001-2009 with a focus on primary anatomic site. <i>British Journal of Haematology</i> , 2014, 165, 67-77.	2.5	127
31	Autoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million US male veterans. <i>Cancer</i> , 2011, 117, 1163-1171.	4.1	116
32	Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era. <i>JAMA Oncology</i> , 2019, 5, 318.	7.1	116
33	Alcohol, Smoking, and Body Size in Relation to Incident Hodgkin's and Non-Hodgkin's Lymphoma Risk. <i>American Journal of Epidemiology</i> , 2007, 166, 697-708.	3.4	112
34	Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. <i>Blood</i> , 2007, 109, 5439-5446.	1.4	109
35	Risk, Risk Factors, and Surveillance of Subsequent Malignant Neoplasms in Survivors of Childhood Cancer: A Review. <i>Journal of Clinical Oncology</i> , 2018, 36, 2145-2152.	1.6	105
36	Non-Hodgkin lymphoma and obesity: A pooled analysis from the InterLymph Consortium. <i>International Journal of Cancer</i> , 2008, 122, 2062-2070.	5.1	104

#	ARTICLE	IF	CITATIONS
37	Risk of Subsequent Malignant Neoplasms in Long-Term Hereditary Retinoblastoma Survivors After Chemotherapy and Radiotherapy. <i>Journal of Clinical Oncology</i> , 2014, 32, 3284-3290.	1.6	103
38	Personal Use of Hair Dye and the Risk of Certain Subtypes of Non-Hodgkin Lymphoma. <i>American Journal of Epidemiology</i> , 2008, 167, 1321-1331.	3.4	98
39	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Diffuse Large B-Cell Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 15-25.	2.1	98
40	Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. <i>Lancet Haematology</i> , 2018, 5, e563-e598.	4.6	97
41	Stomach Cancer Risk After Treatment for Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 3369-3377.	1.6	96
42	Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region. <i>American Journal of Human Genetics</i> , 2014, 95, 462-471.	6.2	96
43	The Epidemic of Non-Hodgkin Lymphoma in the United States: Disentangling the Effect of HIV, 1992-2009. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1069-1078.	2.5	95
44	Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. <i>Nature Communications</i> , 2016, 7, 10933.	12.8	94
45	GWAS of Follicular Lymphoma Reveals Allelic Heterogeneity at 6p21.32 and Suggests Shared Genetic Susceptibility with Diffuse Large B-cell Lymphoma. <i>PLoS Genetics</i> , 2011, 7, e1001378.	3.5	93
46	Cigarette Smoking Prior to First Cancer and Risk of Second Smoking-Associated Cancers Among Survivors of Bladder, Kidney, Head and Neck, and Stage I Lung Cancers. <i>Journal of Clinical Oncology</i> , 2014, 32, 3989-3995.	1.6	93
47	Common Gene Variants in the Tumor Necrosis Factor (TNF) and TNF Receptor Superfamilies and NF- κ B Transcription Factors and Non-Hodgkin Lymphoma Risk. <i>PLoS ONE</i> , 2009, 4, e5360.	2.5	88
48	Consumption of Aspartame-Containing Beverages and Incidence of Hematopoietic and Brain Malignancies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 1654-1659.	2.5	85
49	Radiation-related genomic profile of papillary thyroid carcinoma after the Chernobyl accident. <i>Science</i> , 2021, 372, .	12.6	85
50	Changes in Cancer Registry Coding for Lymphoma Subtypes: Reliability Over Time and Relevance for Surveillance and Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 630-638.	2.5	82
51	A pooled investigation of Toll-like receptor gene variants and risk of non-Hodgkin lymphoma. <i>Carcinogenesis</i> , 2009, 30, 275-281.	2.8	75
52	Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. <i>Nature Communications</i> , 2017, 8, 14175.	12.8	75
53	Associations Between Anthropometry, Cigarette Smoking, Alcohol Consumption, and Non-Hodgkin Lymphoma in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. <i>American Journal of Epidemiology</i> , 2010, 171, 1270-1281.	3.4	74
54	Risk of treatment-related esophageal cancer among breast cancer survivors. <i>Annals of Oncology</i> , 2012, 23, 3081-3091.	1.2	71

#	ARTICLE	IF	CITATIONS
55	A prospective investigation of serum 25-hydroxyvitamin D and risk of lymphoid cancers. <i>International Journal of Cancer</i> , 2009, 124, 979-986.	5.1	70
56	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Marginal Zone Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 52-65.	2.1	70
57	Human leukocyte antigen class I and II alleles in non-Hodgkin lymphoma etiology. <i>Blood</i> , 2010, 115, 4820-4823.	1.4	68
58	Smoking, alcohol use, obesity, and overall survival from non-Hodgkin lymphoma. <i>Cancer</i> , 2010, 116, 2993-3000.	4.1	68
59	Genome-Wide Association Study to Identify Susceptibility Loci That Modify Radiation-Related Risk for Breast Cancer After Childhood Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	66
60	Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era. <i>Blood</i> , 2008, 112, 2694-2702.	1.4	64
61	Hepatitis B or C virus infection and risk of non-Hodgkin lymphoma among solid organ transplant recipients. <i>Haematologica</i> , 2014, 99, 70-73.	3.5	64
62	Risk of Non-Hodgkin Lymphoma Associated with Germline Variation in Genes that Regulate the Cell Cycle, Apoptosis, and Lymphocyte Development. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1259-1270.	2.5	59
63	Prevalence of HIV Infection among U.S. Hodgkin Lymphoma Cases. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 274-281.	2.5	59
64	Current knowledge and future research directions in treatment-related second primary malignancies. <i>European Journal of Cancer, Supplement</i> , 2014, 12, 5-17.	2.2	59
65	A genome-wide association study of marginal zone lymphoma shows association to the HLA region. <i>Nature Communications</i> , 2015, 6, 5751.	12.8	58
66	Immune Mechanisms in Non-Hodgkin Lymphoma: Joint Effects of the TNF G308A and IL10 T3575A Polymorphisms with Non-Hodgkin Lymphoma Risk Factors. <i>Cancer Research</i> , 2007, 67, 5042-5054.	0.9	57
67	Body Mass Index and Risk of Second Obesity-Associated Cancers After Colorectal Cancer: A Pooled Analysis of Prospective Cohort Studies. <i>Journal of Clinical Oncology</i> , 2014, 32, 4004-4011.	1.6	56
68	Associations of Non-Hodgkin Lymphoma (NHL) Risk With Autoimmune Conditions According to Putative NHL Loci. <i>American Journal of Epidemiology</i> , 2015, 181, 406-421.	3.4	54
69	Hair dye use and risk of bladder cancer in the New England bladder cancer study. <i>International Journal of Cancer</i> , 2011, 129, 2894-2904.	5.1	52
70	Rationale and Design of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 1-14.	2.1	52
71	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Peripheral T-Cell Lymphomas: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 66-75.	2.1	52
72	Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. <i>Human Molecular Genetics</i> , 2016, 25, 1663-1676.	2.9	52

#	ARTICLE	IF	CITATIONS
73	Contributions of Subtypes of Non-Hodgkin Lymphoma to Mortality Trends. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 174-179.	2.5	52
74	A Case-Control Study of Occupational Exposure to Trichloroethylene and Non-Hodgkin Lymphoma. <i>Environmental Health Perspectives</i> , 2011, 119, 232-238.	6.0	51
75	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 367-378.	2.0	50
76	Genome-wide association study identifies multiple new loci associated with Ewing sarcoma susceptibility. <i>Nature Communications</i> , 2018, 9, 3184.	12.8	50
77	Genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2) and risk of non-Hodgkin lymphoma. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 537-545.	1.5	48
78	Risk of Second Cancers According to Radiation Therapy Technique and Modality in Prostate Cancer Survivors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 295-302.	0.8	48
79	DRD2 genetic variation in relation to smoking and obesity in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 901-910.	1.5	46
80	Leveraging Epidemiology and Clinical Studies of Cancer Outcomes: Recommendations and Opportunities for Translational Research. <i>Journal of the National Cancer Institute</i> , 2013, 105, 85-94.	6.3	46
81	Incidence of lymphoid neoplasms by subtype among six Asian ethnic groups in the United States, 1996-2004. <i>Cancer Causes and Control</i> , 2008, 19, 1171-1181.	1.8	45
82	Dietary flavonoid intake and non-Hodgkin lymphoma risk. <i>American Journal of Clinical Nutrition</i> , 2008, 87, 1439-1445.	4.7	45
83	Association Between Radioactive Iodine Treatment for Pediatric and Young Adulthood Differentiated Thyroid Cancer and Risk of Second Primary Malignancies. <i>Journal of Clinical Oncology</i> , 2022, 40, 1439-1449.	1.6	45
84	Genetic variation in caspase genes and risk of non-Hodgkin lymphoma: a pooled analysis of 3 population-based case-control studies. <i>Blood</i> , 2009, 114, 264-267.	1.4	42
85	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Mycosis Fungoides and Sezary Syndrome: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 98-105.	2.1	42
86	Increased Risk for Lymphoid and Myeloid Neoplasms in Elderly Solid-Organ Transplant Recipients. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1229-1237.	2.5	41
87	Association of Breast Cancer Risk After Childhood Cancer With Radiation Dose to the Breast and Anthracycline Use. <i>JAMA Pediatrics</i> , 2019, 173, 1171.	6.2	40
88	Hair dye use, genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma. <i>Carcinogenesis</i> , 2007, 28, 1759-1764.	2.8	39
89	Organochlorine exposure, immune gene variation, and risk of non-Hodgkin lymphoma. <i>Blood</i> , 2009, 113, 1899-1905.	1.4	39
90	Lifestyle and Dietary Factors in Relation to Risk of Chronic Myeloid Leukemia in the NIH-AARP Diet and Health Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 848-854.	2.5	39

#	ARTICLE	IF	CITATIONS
91	Subtype-specific incidence rates of lymphoid malignancies in Hong Kong compared to the United States, 2001-2010. <i>Cancer Epidemiology</i> , 2016, 42, 15-23.	1.9	39
92	Risk of diffuse large B-cell lymphoma after solid organ transplantation in the United States. <i>American Journal of Hematology</i> , 2014, 89, 714-720.	4.1	37
93	Risk of esophageal cancer following radiotherapy for Hodgkin lymphoma. <i>Haematologica</i> , 2014, 99, e193-e196.	3.5	37
94	Hepatitis C virus infection and risk of posttransplantation lymphoproliferative disorder among solid organ transplant recipients. <i>Blood</i> , 2007, 110, 4599-4605.	1.4	35
95	Reproductive factors, exogenous hormone use and risk of lymphoid neoplasms among women in the National Institutes of Health AARP Diet and Health Study Cohort. <i>International Journal of Cancer</i> , 2009, 124, 2737-2743.	5.1	35
96	Mortality After Breast Cancer Among Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2120-2130.	1.6	35
97	Menstrual and Reproductive Factors and Risk of Non-Hodgkin's Lymphoma among Connecticut Women. <i>American Journal of Epidemiology</i> , 2004, 160, 766-773.	3.4	34
98	Genetic variation in Th1/Th2 pathway genes and risk of non-Hodgkin lymphoma: a pooled analysis of three population-based case-control studies. <i>British Journal of Haematology</i> , 2011, 153, 341-350.	2.5	34
99	PRRC2A and BCL2L11 gene variants influence risk of non-Hodgkin lymphoma: results from the InterLymph consortium. <i>Blood</i> , 2012, 120, 4645-4648.	1.4	34
100	Plasma Cell Neoplasms in US Solid Organ Transplant Recipients. <i>American Journal of Transplantation</i> , 2013, 13, 1523-1532.	4.7	34
101	HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. <i>Cancer Research</i> , 2018, 78, 4086-4096.	0.9	34
102	Meat Intake Is Not Associated with Risk of Non-Hodgkin Lymphoma in a Large Prospective Cohort of U.S. Men and Women. <i>Journal of Nutrition</i> , 2012, 142, 1074-1080.	2.9	32
103	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Lymphoplasmacytic Lymphoma/Waldenström's Macroglobulinemia: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 87-97.	2.1	32
104	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Sporadic Burkitt Lymphoma/Leukemia: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 106-114.	2.1	32
105	Medical History, Lifestyle, and Occupational Risk Factors for Hairy Cell Leukemia: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 115-124.	2.1	31
106	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Mantle Cell Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 76-86.	2.1	31
107	Blood Transfusion and Risk of Non-Hodgkin's Lymphoma in Connecticut Women. <i>American Journal of Epidemiology</i> , 2004, 160, 325-330.	3.4	30
108	Increased pancreatic cancer risk following radiotherapy for testicular cancer. <i>British Journal of Cancer</i> , 2016, 115, 901-908.	6.4	30

#	ARTICLE	IF	CITATIONS
109	Second Primary Cancers After Intensity-Modulated vs 3-Dimensional Conformal Radiation Therapy for Prostate Cancer. <i>JAMA Oncology</i> , 2016, 2, 1368.	7.1	30
110	Hodgkin Lymphoma Among US Solid Organ Transplant Recipients. <i>Transplantation</i> , 2010, 90, 1011-1015.	1.0	29
111	A pooled analysis of three studies evaluating genetic variation in innate immunity genes and non-Hodgkin lymphoma risk. <i>British Journal of Haematology</i> , 2011, 152, 721-726.	2.5	29
112	Cause-Specific Mortality Following Initial Chemotherapy in a Population-Based Cohort of Patients With Classical Hodgkin Lymphoma, 2000-2016. <i>Journal of Clinical Oncology</i> , 2020, 38, 4149-4162.	1.6	29
113	Residential proximity to industrial combustion facilities and risk of non-Hodgkin lymphoma: a case-control study. <i>Environmental Health</i> , 2013, 12, 20.	4.0	28
114	Risk of non-Hodgkin lymphoma after radiotherapy for solid cancers. <i>Leukemia and Lymphoma</i> , 2013, 54, 1691-1697.	1.3	28
115	Burkitt lymphoma risk in U.S. solid organ transplant recipients. <i>American Journal of Hematology</i> , 2013, 88, 245-250.	4.1	28
116	Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes. <i>Genetic Epidemiology</i> , 2019, 43, 844-863.	1.3	28
117	Spatial-temporal analysis of non-Hodgkin lymphoma in the NCI-SEER NHL case-control study. <i>Environmental Health</i> , 2011, 10, 63.	4.0	27
118	Census and Geographic Differences between Respondents and Nonrespondents in a Case-Control Study of Non-Hodgkin Lymphoma. <i>American Journal of Epidemiology</i> , 2007, 167, 350-361.	3.4	26
119	Risk Factors for Melanoma Among Survivors of Non-Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 3096-3104.	1.6	26
120	Patterns of Cause-Specific Mortality Among 2053 Survivors of Retinoblastoma, 1914-2016. <i>Journal of the National Cancer Institute</i> , 2019, 111, 961-969.	6.3	26
121	Molecular characteristics of diffuse large B-cell lymphoma in human immunodeficiency virus-infected and -uninfected patients in the pre-highly active antiretroviral therapy and pre-rituximab era. <i>Leukemia and Lymphoma</i> , 2014, 55, 551-557.	1.3	24
122	Recommendations for Long-Term Follow-up of Adults with Heritable Retinoblastoma. <i>Ophthalmology</i> , 2020, 127, 1549-1557.	5.2	24
123	Radiation Dose and Subsequent Risk for Stomach Cancer in Long-term Survivors of Cervical Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 922-929.	0.8	23
124	Comprehensive Evaluation of Medical Conditions Associated with Risk of Non-Hodgkin Lymphoma using Medicare Claims (MedWAS). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1105-1113.	2.5	23
125	Risk of Second Malignancies in Solid Organ Transplant Recipients Who Develop Keratinocyte Cancers. <i>Cancer Research</i> , 2017, 77, 4196-4203.	0.9	22
126	Risk of subsequent myeloid neoplasms after radiotherapy treatment for a solid cancer among adults in the United States, 2000-2014. <i>Leukemia</i> , 2018, 32, 2580-2589.	7.2	22

#	ARTICLE	IF	CITATIONS
127	Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. <i>Blood</i> , 2018, 131, 2541-2551.	1.4	21
128	Smoking, variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma: a pooled analysis within the InterLymph consortium. <i>Cancer Causes and Control</i> , 2013, 24, 125-134.	1.8	20
129	Polycyclic aromatic hydrocarbons: determinants of residential carpet dust levels and risk of non-Hodgkin lymphoma. <i>Cancer Causes and Control</i> , 2016, 27, 1-13.	1.8	20
130	Risk of second primary papillary thyroid cancer among adult cancer survivors in the United States, 2000-2015. <i>Cancer Epidemiology</i> , 2020, 64, 101664.	1.9	20
131	No Association between Radiation Dose from Pediatric CT Scans and Risk of Subsequent Hodgkin Lymphoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 804-806.	2.5	19
132	Radiotherapy for ductal carcinoma in situ and risk of second non-breast cancers. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 299-306.	2.5	19
133	A High-risk Haplotype for Premature Menopause in Childhood Cancer Survivors Exposed to Gonadotoxic Therapy. <i>Journal of the National Cancer Institute</i> , 2018, 110, 895-904.	6.3	19
134	Bone and Soft Tissue Sarcoma Risk in Long-Term Survivors of Hereditary Retinoblastoma Treated With Radiation. <i>Journal of Clinical Oncology</i> , 2019, 37, 3436-3445.	1.6	19
135	Blood transfusion, anesthesia, surgery and risk of non-Hodgkin lymphoma in a population-based case-control study. <i>International Journal of Cancer</i> , 2008, 123, 888-894.	5.1	18
136	Polymorphisms in DNA repair genes and risk of non-Hodgkin lymphoma in a pooled analysis of three studies. <i>British Journal of Haematology</i> , 2010, 151, 239-244.	2.5	18
137	Genome-Wide Association Study in Irradiated Childhood Cancer Survivors Identifies HTR2A for Subsequent Basal Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2019, 139, 2042-2045.e8.	0.7	18
138	Genetic variation in POT1 and risk of thyroid subsequent malignant neoplasm: A report from the Childhood Cancer Survivor Study. <i>PLoS ONE</i> , 2020, 15, e0228887.	2.5	18
139	Variations in Chromosomes 9 and 6p21.3 with Risk of Non-Hodgkin Lymphoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 42-49.	2.5	17
140	Converting Epidemiologic Studies of Cancer Etiology to Survivorship Studies: Approaches and Challenges. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 875-880.	2.5	17
141	HLA and Risk of Diffuse Large B cell Lymphoma After Solid Organ Transplantation. <i>Transplantation</i> , 2016, 100, 2453-2460.	1.0	17
142	Risk of therapy-related myelodysplastic syndrome/acute myeloid leukemia after childhood cancer: a population-based study. <i>Leukemia</i> , 2019, 33, 2947-2978.	7.2	17
143	The Future of Childhood Cancer Survivorship. <i>Pediatric Clinics of North America</i> , 2020, 67, 1237-1251.	1.8	17
144	Risk of Rare Cancers Among Solid Organ Transplant Recipients. <i>Journal of the National Cancer Institute</i> , 2021, 113, 199-207.	6.3	17

#	ARTICLE	IF	CITATIONS
145	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Adult Acute Lymphocytic Leukemia: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 125-129.	2.1	16
146	Successful use of whole genome amplified DNA from multiple source types for high-density Illumina SNP microarrays. <i>BMC Genomics</i> , 2018, 19, 182.	2.8	16
147	Subsequent Primary Neoplasms. <i>Pediatric Clinics of North America</i> , 2020, 67, 1135-1154.	1.8	16
148	Long-term risk of subsequent cancer incidence among hereditary and nonhereditary retinoblastoma survivors. <i>British Journal of Cancer</i> , 2021, 124, 1312-1319.	6.4	16
149	Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults. <i>JAMA Network Open</i> , 2022, 5, e223461.	5.9	16
150	Genetic variation in catechol-O-methyltransferase (COMT) and obesity in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial. <i>Human Genetics</i> , 2007, 122, 41-49.	3.8	15
151	Genetic variation in cell cycle and apoptosis related genes and multiple myeloma risk. <i>Leukemia Research</i> , 2009, 33, 1609-1614.	0.8	15
152	Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. <i>Lupus Science and Medicine</i> , 2017, 4, e000187.	2.7	15
153	Mutual Risks of Cutaneous Melanoma and Specific Lymphoid Neoplasms: Second Cancer Occurrence and Survival. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1248-1258.	6.3	15
154	Prevalence of pathogenic/likely pathogenic variants in the 24 cancer genes of the ACMG Secondary Findings v2.0 list in a large cancer cohort and ethnicity-matched controls. <i>Genome Medicine</i> , 2018, 10, 99.	8.2	15
155	Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia. <i>Nature Communications</i> , 2018, 9, 4182.	12.8	15
156	Mating Habits of New Zealand Dusky Dolphins. , 2010, , 151-176.		14
157	Risk factors for non-Hodgkin lymphoma subtypes defined by histology and t(14;18) in a population-based case-control study. <i>International Journal of Cancer</i> , 2011, 129, 938-947.	5.1	14
158	Inherited genetic variation and overall survival following follicular lymphoma. <i>American Journal of Hematology</i> , 2012, 87, 724-726.	4.1	13
159	Radiation Dose to the Esophagus From Breast Cancer Radiation Therapy, 1943-1996: An International Population-Based Study of 414 Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 694-701.	0.8	13
160	Stomach Cancer Following Hodgkin Lymphoma, Testicular Cancer and Cervical Cancer: A Pooled Analysis of Three International Studies with a Focus on Radiation Effects. <i>Radiation Research</i> , 2017, 187, 186.	1.5	13
161	Dose-volume effects of breast cancer radiation therapy on the risk of second oesophageal cancer. <i>Radiotherapy and Oncology</i> , 2020, 151, 33-39.	0.6	13
162	Contribution of Polygenic Risk to Hypertension Among Long-Term Survivors of Childhood Cancer. <i>JACC: CardioOncology</i> , 2021, 3, 76-84.	4.0	13

#	ARTICLE	IF	CITATIONS
163	Human Leukocyte Antigen Class I and II Alleles and Overall Survival in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma. <i>Scientific World Journal, The</i> , 2011, 11, 2062-2070.	2.1	12
164	Role of Germline Genetics in Identifying Survivors at Risk for Adverse Effects of Cancer Treatment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 775-786.	3.8	12
165	Risk for malignancies of infectious etiology among adult survivors of specific non-Hodgkin lymphoma subtypes. <i>Blood Advances</i> , 2019, 3, 1961-1969.	5.2	12
166	Generalizability of "GWAS Hits" in Clinical Populations: Lessons from Childhood Cancer Survivors. <i>American Journal of Human Genetics</i> , 2020, 107, 636-653.	6.2	12
167	Genetic variation in N-acetyltransferases 1 and 2, cigarette smoking, and risk of non-Hodgkin lymphoma. <i>Cancer Causes and Control</i> , 2010, 21, 127-133.	1.8	11
168	Variation in Effects of Non-Hodgkin Lymphoma Risk Factors According to the Human Leukocyte Antigen (HLA)-DRB1*01:01 Allele and Ancestral Haplotype 8.1. <i>PLoS ONE</i> , 2011, 6, e26949.	2.5	11
169	A step toward slaying the hydra of second cancers. <i>Nature Medicine</i> , 2011, 17, 924-925.	30.7	11
170	Prediction of the location and size of the stomach using patient characteristics for retrospective radiation dose estimation following radiotherapy. <i>Physics in Medicine and Biology</i> , 2013, 58, 8739-8753.	3.0	11
171	Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in the Childhood Cancer Survivor Study. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab007.	2.9	11
172	Polygenic Risk Score Improves Risk Stratification and Prediction of Subsequent Thyroid Cancer after Childhood Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 2096-2104.	2.5	11
173	Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. <i>Lancet Haematology</i> , 2022, 9, e374-e384.	4.6	11
174	Cancer risk following lymphoid malignancies among HIV-infected people. <i>Aids</i> , 2020, 34, 1237-1245.	2.2	10
175	Role of radiotherapy and chemotherapy in the risk of leukemia after childhood cancer: An international pooled analysis. <i>International Journal of Cancer</i> , 2021, 148, 2079-2089.	5.1	10
176	Encouraging participation in medical research: what strategies work?. <i>Journal of Clinical Epidemiology</i> , 2008, 61, 969-970.	5.0	9
177	Pooling Prospective Studies to Investigate the Etiology of Second Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1598-1608.	2.5	9
178	Subsequent Neoplasm Risk Associated With Rare Variants in DNA Damage Response and Clinical Radiation Sensitivity Syndrome Genes in the Childhood Cancer Survivor Study. <i>JCO Precision Oncology</i> , 2020, 4, 926-936.	3.0	9
179	The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma. <i>Blood</i> , 2021, 138, 785-789.	1.4	9
180	Stomach cancer risk following radiotherapy for testicular cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4536-4536.	1.6	9

#	ARTICLE	IF	CITATIONS
181	Investigation of spatio-temporal cancer clusters using residential histories in a case-control study of non-Hodgkin lymphoma in the United States. <i>Environmental Health</i> , 2015, 14, 48.	4.0	8
182	Non-Hodgkin Lymphoma, Body Mass Index, and Cytokine Polymorphisms: A Pooled Analysis from the InterLymph Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1061-1070.	2.5	8
183	Cause-specific mortality in individuals with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia, 2000-2016. <i>British Journal of Haematology</i> , 2020, 189, 1107-1118.	2.5	8
184	Cause-specific mortality following polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the US population, 2001-2017. <i>American Journal of Hematology</i> , 2021, 96, E451-E454.	4.1	8
185	Association of Treatment for Hodgkin Lymphoma With Estrogen Receptor Status of Subsequent Breast Cancers. <i>JAMA Oncology</i> , 2018, 4, 414.	7.1	7
186	Risk of Second Primary Bone and Soft-Tissue Sarcomas Among Young Adulthood Cancer Survivors. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz043.	2.9	7
187	Telomere Length-Associated Genetic Variants and the Risk of Thyroid Cancer in Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study (CCSS). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 417-419.	2.5	7
188	Risk factors for the development of cutaneous melanoma after allogeneic hematopoietic cell transplantation. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 762-772.	1.2	7
189	Genome-wide Association Studies Reveal Novel Locus With Sex-/Therapy-Specific Fracture Risk Effects in Childhood Cancer Survivors. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 685-695.	2.8	7
190	Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab era. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2011, 2, 245-52.	0.4	7
191	Dissecting lymphoma incidence to inform epidemiologic and clinical research. <i>Leukemia and Lymphoma</i> , 2013, 54, 1575-1576.	1.3	6
192	A NOVEL METHOD TO ESTIMATE LYMPHOCYTE DOSE AND APPLICATION TO PEDIATRIC AND YOUNG ADULT CT PATIENTS IN THE UNITED KINGDOM. <i>Radiation Protection Dosimetry</i> , 2018, 178, 116-121.	0.8	6
193	Low-frequency variation near common germline susceptibility loci are associated with risk of Ewing sarcoma. <i>PLoS ONE</i> , 2020, 15, e0237792.	2.5	6
194	Genetically Determined Height and Risk of Non-hodgkin Lymphoma. <i>Frontiers in Oncology</i> , 2019, 9, 1539.	2.8	6
195	Genetic variation in the body mass index of adult survivors of childhood acute lymphoblastic leukemia: A report from the Childhood Cancer Survivor Study and the St. Jude Lifetime Cohort. <i>Cancer</i> , 2021, 127, 310-318.	4.1	6
196	Increased Risk of Skin Cancer in 1,851 Long-Term Retinoblastoma Survivors. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2849-2857.e3.	0.7	6
197	Clinical and genetic risk factors for radiation-associated ototoxicity: A report from the Childhood Cancer Survivor Study and the St. Jude Lifetime Cohort. <i>Cancer</i> , 2021, 127, 4091-4102.	4.1	6
198	Radiogenomic Predictors of Adverse Effects following Charged Particle Therapy. <i>International Journal of Particle Therapy</i> , 2018, 5, 103-113.	1.8	6

#	ARTICLE	IF	CITATIONS
199	LIM domain only 2 protein expression, <i>LMO2</i> germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era. <i>Leukemia and Lymphoma</i> , 2012, 53, 1105-1112.	1.3	5
200	Sex-Related Effect on Immunotherapy Response: Implications and Opportunities. <i>Journal of the National Cancer Institute</i> , 2019, 111, 749-750.	6.3	5
201	Benign Tumors in Long-Term Survivors of Retinoblastoma. <i>Cancers</i> , 2021, 13, 1773.	3.7	5
202	Body mass index and survival of patients with lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 2671-2678.	1.3	5
203	Subsequent Cancers in Patients Affected with Moderate or Severe Chronic Graft-versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 937.e1-937.e7.	1.2	5
204	Risk prediction of anthracycline-related cardiomyopathy (AC) in childhood cancer survivors (CCS): A COG-ALTE03N1 and CCSS report.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10015-10015.	1.6	5
205	SLC6A3 and body mass index in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. <i>BMC Medical Genetics</i> , 2009, 10, 9.	2.1	4
206	Associations between non-Hodgkin lymphoma and renal cell carcinoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 2201-2202.	1.3	4
207	Household endotoxin levels and the risk of non-Hodgkin lymphoma. <i>Cancer Causes and Control</i> , 2013, 24, 357-364.	1.8	4
208	Cancer risk following post-transplant lymphoproliferative disorders in solid organ transplant recipients. <i>British Journal of Haematology</i> , 2019, 186, 347-351.	2.5	4
209	Common genetic polymorphisms contribute to the association between chronic lymphocytic leukaemia and non-melanoma skin cancer. <i>International Journal of Epidemiology</i> , 2021, 50, 1325-1334.	1.9	4
210	Comparison of Radiation Dose Reconstruction Methods to Investigate Late Adverse Effects of Radiotherapy for Childhood Cancer: A Report from the Childhood Cancer Survivor Study. <i>Radiation Research</i> , 2019, 193, 95.	1.5	4
211	A Novel Locus on 6p21.2 for Cancer Treatment-Induced Cardiac Dysfunction Among Childhood Cancer Survivors. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1109-1116.	6.3	4
212	Smoking and lymphoma: a small part of a complex story. <i>Leukemia and Lymphoma</i> , 2012, 53, 1853-1854.	1.3	3
213	Racial and ethnic differences in risk of second primary cancers among prostate cancer survivors. <i>Cancer Causes and Control</i> , 2020, 31, 1011-1019.	1.8	3
214	Testicular Cancer as a Model for Understanding the Impact of Evolving Treatment Strategies on the Long-Term Health of Cancer Survivors. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa013.	2.9	3
215	Oncologic Therapy for Solid Tumors Alters the Risk of Clonal Hematopoiesis. <i>Blood</i> , 2018, 132, 747-747.	1.4	3
216	Re: No Increased Risk of non-Hodgkin's Lymphoma with Steroids, Estrogens and Psychotropics (Netherlands). <i>Cancer Causes and Control</i> , 2004, 15, 433-434.	1.8	2

#	ARTICLE	IF	CITATIONS
217	Evolving Strategies in Epidemiologic Research on Radiation and Cancer. <i>Radiation Research</i> , 2011, 176, 527-532.	1.5	2
218	Triple jeopardy for Hodgkin lymphoma survivors?. <i>Blood</i> , 2014, 124, 309-310.	1.4	2
219	Using patient-reported outcomes to improve survivorship care. <i>Blood</i> , 2020, 135, 1819-1820.	1.4	2
220	Breast Cancer After Childhood, Adolescent, and Young Adult Cancer: It's Not Just About Chest Radiation. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 736-745.	3.8	2
221	Incidence of myeloid malignancies by subtype in Hong Kong and comparisons with Asian and white men and women in the United States. <i>Leukemia and Lymphoma</i> , 2022, 63, 1917-1924.	1.3	2
222	Re: Hair dye use, genetic variation in N -acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma, author response. <i>Carcinogenesis</i> , 2008, 29, 1084-1085.	2.8	1
223	Sex- and Subtype-Specific Analysis of H2AFX Polymorphisms in Non-Hodgkin Lymphoma. <i>PLoS ONE</i> , 2013, 8, e74619.	2.5	1
224	Assessment of surveillance versus etiologic factors in the reciprocal association between papillary thyroid cancer and breast cancer. <i>Cancer Epidemiology</i> , 2021, 74, 101985.	1.9	1
225	Subsequent neoplasm risk associated with rare variants in DNA repair and clinical radiation sensitivity syndrome genes: A report from the Childhood Cancer Survivor Study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10028-10028.	1.6	1
226	Emerging Risks of AML/MDS and Other Myeloid Neoplasms Following Chemotherapy for First Primary Malignancy, 2000-2012. <i>Blood</i> , 2015, 126, 562-562.	1.4	1
227	A high-risk genetic profile for premature menopause (PM) in childhood cancer survivors (CCS) exposed to gonadotoxic therapy: A report from the St. Jude Lifetime Cohort (SJLIFE) and Childhood Cancer Survivor Study (CCSS).. <i>Journal of Clinical Oncology</i> , 2017, 35, 10502-10502.	1.6	1
228	Shedding light on UVR and Hodgkin lymphoma. <i>Blood</i> , 2013, 122, 3395-3397.	1.4	0
229	RE: The Association of Dyslipidemia With Chronic Lymphocytic Leukemia: A Population-Based Study. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	0
230	Novel Insights Into the Long-Term Immune Health of Diffuse Large B-Cell Lymphoma Survivors. <i>Journal of Clinical Oncology</i> , 2020, 38, 1648-1650.	1.6	0
231	Genetic and treatment risks for diabetes mellitus (DM) in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS) and St. Jude Lifetime (SJLIFE) cohorts.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10014-10014.	1.6	0
232	Germline Single Nucleotide Polymorphisms (SNPs) in IL1A, IL6, IL10, and IFNGR2 in Combination with Clinical with Demographic Factors Predict Overall Survival in Diffuse Large B-Cell Lymphoma (DLBCL).. <i>Blood</i> , 2006, 108, 2028-2028.	1.4	0
233	Host Immunogenetic Single Nucleotide Polymorphisms (SNPs) Predict Overall Survival in Small Lymphocytic Lymphoma.. <i>Blood</i> , 2006, 108, 2396-2396.	1.4	0
234	Abstract 5644: Second cancer risks among lymphoma survivors in the SEER-Medicare linked dataset. , 2010, , .		0

#	ARTICLE	IF	CITATIONS
235	Abstract 1025: Risk of diffuse large B-cell lymphoma in solid organ transplant recipients. , 2012, , .		0
236	Abstract 4490: Molecular characteristics of diffuse large B-cell lymphoma in HIV-positive and HIV-negative patients. , 2012, , .		0
237	Abstract 1333: Specific RB1 mutations and risk of subsequent neoplasms among survivors of hereditary retinoblastoma.. , 2013, , .		0
238	Risk factors for melanoma among survivors of non-Hodgkin lymphoma in the U.S. elderly population.. Journal of Clinical Oncology, 2014, 32, 1533-1533.	1.6	0
239	Risk of subsequent malignant neoplasms in long-term retinoblastoma survivors following chemotherapy and radiotherapy.. Journal of Clinical Oncology, 2014, 32, 10079-10079.	1.6	0
240	Second Tumors in Retinoblastoma Survivors. Essentials in Ophthalmology, 2015, , 105-112.	0.1	0
241	Abstract 3725: Subsequent gastrointestinal cancer risks of childhood and early adulthood cancer survivors. , 2015, , .		0
242	Abstract LB-184: Risk factors for lung cancer among survivors of non-Hodgkin lymphoma. , 2015, , .		0
243	Abstract 934: A pooled investigation of circulating adiponectin levels and risk of multiple myeloma. , 2015, , .		0
244	Incidence and Patient Survival of Myeloproliferative Neoplasms (MPNs) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs) in the United States: A Population-Based View of the Modern Diagnostic Era. Blood, 2015, 126, 2806-2806.	1.4	0
245	Spectrum of pediatric and young adult cancer survivors at risk of developing subsequent sarcomas.. Journal of Clinical Oncology, 2016, 34, 10572-10572.	1.6	0
246	Genome-wide association study of meningioma as a subsequent neoplasm: A report from the Childhood Cancer Survivor Study (CCSS) and St. Jude Lifetime Cohort (SJLIFE).. Journal of Clinical Oncology, 2016, 34, 10510-10510.	1.6	0
247	Abstract 2691: Genome-wide association study identifies two susceptibility loci that modify radiation-related risk for breast cancer after childhood cancer: A report from the Childhood Cancer Survivor Study and St. Jude Lifetime Cohort. , 2016, , .		0
248	Abstract 5206: Recent incidence trends of lymphoid malignancies in Hong Kong, 2001-2010. , 2016, , .		0
249	Abstract 5207: Comparison of subtype-specific incidence rates of lymphoid malignancies in Hong Kong and the United States. , 2016, , .		0
250	Risk of subsequent breast cancer after radiotherapy according to hormone-receptor status: A nested case-control study in the Childhood Cancer Survivor Study (CCSS).. Journal of Clinical Oncology, 2017, 35, 10520-10520.	1.6	0
251	Abstract LB-236: Risk of tMDS/AML after chemotherapy for first primary lymphoid malignancy, 2000-2013. , 2017, , .		0
252	Abstract 1318: A genome-wide association study of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma demonstrates association with chromosome 6. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
253	Abstract 2970: Multiple new susceptibility loci identified in genome-wide association study of Ewing sarcoma. , 2018, , .		0
254	Abstract 2966: A genome-wide scan identifies a new locus associated with pediatric rhabdomyosarcoma. , 2018, , .		0
255	Abstract 600: Telomere length-associated genetic variants and the risk of thyroid cancer after childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS). , 2018, , .		0
256	Abstract A13: Genome-wide association study identifies multiple new loci associated with Ewing sarcoma susceptibility. , 2018, , .		0
257	Risk Factors for the Development of Cutaneous Melanoma after Allogeneic Hematopoietic Cell Transplantation. Blood, 2018, 132, 249-249.	1.4	0
258	Genome-wide association study using whole-genome sequencing to identify a novel locus associated with cardiomyopathy risk in adult survivors of childhood cancer: Utility of a two-stage analytic approach.. Journal of Clinical Oncology, 2019, 37, 1516-1516.	1.6	0
259	Polygenic risk of subsequent thyroid cancer after childhood cancer: A report from St. Jude lifetime cohort (SJLIFE) and Childhood Cancer Survivor Study (CCSS).. Journal of Clinical Oncology, 2019, 37, 10060-10060.	1.6	0
260	Combined effect of radiotherapy and anthracyclines on risk of breast cancer among female childhood cancer survivors: A report from the Childhood Cancer Survivor Study (CCSS).. Journal of Clinical Oncology, 2019, 37, 10053-10053.	1.6	0
261	Cause-specific mortality in survivors of lymphoplasmacytic lymphoma (LPL) and waldenstrom macroglobulinemia (WM).. Journal of Clinical Oncology, 2019, 37, e19056-e19056.	1.6	0
262	Abstract LB-304: Oncologic therapy for solid tumors alters the risk of clonal hematopoiesis. , 2019, , .		0
263	Abstract 3122: A functionalPOT1variant and risk of thyroid subsequent malignant neoplasm: A report from the Childhood Cancer Survivor Study. , 2019, , .		0
264	Population-Based, Cause-Specific Risk of Non-Lymphoma Deaths Among 20,491 Adults with Classical Hodgkin Lymphoma (cHL) Treated with Initial Chemotherapy in the United States, 2000-2015. Blood, 2019, 134, 4034-4034.	1.4	0
265	Clinical and genetic risk factors for radiation-associated ototoxicity: A report from the childhood cancer survivor study and the St. Jude Lifetime Cohort.. Journal of Clinical Oncology, 2020, 38, 10550-10550.	1.6	0
266	<i>HAGHL</i> genetic variants increase first fracture risk (FFR) in female childhood cancer survivors: A report from the Childhood Cancer Survivor Study (CCSS) and St. Jude Lifetime Cohort Study (SJLIFE).. Journal of Clinical Oncology, 2020, 38, 10554-10554.	1.6	0
267	Abstract 1056: Elevated incidence of rare cancers among solid organ transplant recipients (SOTRs) in the United States. , 2020, , .		0
268	Abstract 5703: Oncologic therapy shapes the fitness landscape of clonal hematopoiesis. , 2020, , .		0
269	Body Mass Index and Survival of Patients with Lymphoma. Blood, 2020, 136, 2-3.	1.4	0
270	Title is missing!. , 2020, 15, e0228887.		0

#	ARTICLE	IF	CITATIONS
271	Title is missing!. , 2020, 15, e0228887.		0
272	Title is missing!. , 2020, 15, e0228887.		0
273	Title is missing!. , 2020, 15, e0228887.		0
274	Title is missing!. , 2020, 15, e0237792.		0
275	Title is missing!. , 2020, 15, e0237792.		0
276	Title is missing!. , 2020, 15, e0237792.		0
277	Title is missing!. , 2020, 15, e0237792.		0
278	Reply to P. PetranoviÄŤ OvÄriÄek et al. Journal of Clinical Oncology, 0, , .	1.6	0